|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Integra LifeSciences Holdings Corp. (Nasdaq:IART), a manufacturer of neuro and plastic surgical products. |
|---|---|
| Transferring Party | IsoTis Inc. (Nasdaq:ISOT), a manufacturer of bone graft substitutes and medical devices focusing on the orthobiologics market. |
| Sector | Medical Devices |
| Date | October 29, 2007 |
| Analysis Enhances Integra's orthobiologics portfolio, broadens its international presence in the regenerative medicine market and increases its sales capacity in neurosurgery, spine and extremity reconstruction markets. Integra expects annual cost savings of about $10m for 08. Deal value - $51m on $44.6m of revenue (1.2x) and negative EBITDA. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |